Amirhosein Kefayat | Pharmaceutical Chemistry | Top Pharmaceutical Scientist Award

Published on by Top Pharmaceutical

Dr. Amirhosein Kefayat | Pharmaceutical Chemistry | Top Pharmaceutical Scientist Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a distinguished physician-scientist specializing in oncology, nanomedicine, cancer immunotherapy, and radiation oncology, with extensive experience in translational research and clinical studies. He earned his Doctorate of Medicine (MD) from Isfahan University of Medical Sciences in 2019 and has since advanced his qualifications with multiple prestigious certifications, including full registration with the General Medical Council (UK) and ongoing ECFMG certification for the United States.Currently serving as a Clinical Research Fellow at the Institute of Genetics & Cancer, University of Edinburgh & NHS Lothian (UK), Dr. Kefayat contributes to UK-wide clinical trials such as ACESO, BIOPIC, DEFINE, PROFILE, PAN-IBD, and Gut Cell Atlas. He also leads systematic review and meta-analysis teams, influencing major clinical guidelines like the British Society of Gastroenterology 2024 update.Previously, as a Clinical Research Fellow at the Dept. of Radiotherapy & Oncology, Arak University of Medical Sciences (Iran), he led multiple high-impact research projects, resulting in numerous publications, international conference presentations, patents, and national research grants (INSF, NIMAD).Dr. Kefayat has published extensively in top Q1 journals such as Carbohydrate Polymers, Biosensors & Bioelectronics, Vaccine, Scientific Reports, Journal of Biomolecular Structure & Dynamics, and Nanomedicine. His work on novel cancer vaccines, wound healing biomaterials, and radiosensitizers ranks among the top 1–10% most-cited papers worldwide, reflecting his global research impact.His notable accolades include recognition as the top 0.5% of scholars worldwide (2024), membership in Iran’s National Elites Foundation, and multiple national research grants. His patented biomaterial for diabetic wound healing demonstrates his commitment to bridging laboratory research with clinical application.

Profile: Google Scholar

Featured Publications

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., & Amini Baghbadorani, M. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., Rafienia, M., & Navid, S. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Agheb, M. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

Karizmeh, M. S., Poursamar, S. A., Kefayat, A., Farahbakhsh, Z., & Rafienia, M. (2022). An in vitro and in vivo study of PCL/chitosan electrospun mat on polyurethane/propolis foam as a bilayer wound dressing. Biomaterials Advances, 135, 112667.

Ghahremani, F., Shahbazi-Gahrouei, D., Kefayat, A., Motaghi, H., & Amouheidari, A. (2018). AS1411 aptamer conjugated gold nanoclusters as a targeted radiosensitizer for megavoltage radiation therapy of 4T1 breast cancer cells. RSC Advances, 8(8), 4249–4258.

Safavi, A., Kefayat, A., Abiri, A., Mahdevar, E., Behnia, A. H., & Ghahremani, F. (2019). In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma. Molecular Immunology, 112, 93–102.